PACTR202012892855610尚未招募未知
A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19
Oncotelic Incorporated0 个研究点目标入组 120 人开始时间: 2020年11月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •1. Male or female subjects of =18 to 60 years of age.
- •2. Subjects willing to give informed consent and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- •3. Confirmed case of COVID-19 infection by RT-PCR and mild and moderate (without oxygen therapy or assisted ventilation) cases of COVID-19. Scores of 2-4 on the WHO Clinical Progression Scale
- •4. Time interval between symptoms onset and randomization of no more than 7 days
- •5. One or more of the following symptoms:
- •? Sore throat
- •Nasal congestion
- •? Loss of smell
- •? Loss of taste
- •6. Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 30 days after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
排除标准
- •1. Subjects with history of severe infections (pneumonia, septicemia, etc.), severe cardiac or pulmonary diseases, or received immunosuppressive therapy or other investigational drugs within the previous 30 days of screening
- •2. Known or suspected hypersensitivity to Artemisinin
- •3. Women of child bearing potential who are currently pregnant, lactating or who are not willing to use contraception during the entire duration of the study
- •4. Men who are unwilling to use contraception while receiving investigational product
- •5. Subjects with history of severe disease other than COVID-19 which is expected to prevent compliance with the present protocol
- •6. Subjects with history of severe renal and hepatic impairment. (creatine =2 mg/dl; liver enzymes and bilirubin 2.5 times ULN;alkaline phosphatase 1.5 times ULN)
- •7. Recent treatment with Artemisinin or Artemisinin based antimalarials in the past 7 days
- •8. Known history of failure to control systemic fungal, bacterial or viral infection
- •9. Patients with the following co-morbidities: insulin-dependent diabetes, hypertension with cardiac symptoms, morbid obesity with diabetes and/or hypertension
- •10. Subjects with known human immunodeficiency virus (HIV) or hepatitis B or C classes of active viral infection
- •11. Have a history of neurological or psychiatric disorders, including epilepsy or dementia
- •12. Subjects for whom ventilator support is required at screening
- •13. Patients not willing to stay in hospital for 5 days of isolation following diagnosis of Covid-19
- •14. Subjects not willing to give their informed consent to participate in the clinical trial Subjects having uncontrolled diabetes, uncontrolled hypertension.
- •16. According to the investigator's judgment, there are concomitant diseases with a serious safety hazard or affect the subject
- •17. Using other experimental drugs or participating in other clinical trials in the prior one month.
研究者
相似试验
招募中
4 期
Phase IV study to evaluate the safety and efficacy of Artemisinin- a herbal supplement on COVID-19 subjectsCTRI/2020/09/028044Windlas Biotech Private Limited
进行中（未招募）
1 期
Evaluation of Equine antibody treatment in patient with COVID 19 infectioCTRI/2021/02/031566Bharat Serums and Vaccines ltd
招募中
3 期
A comparative Phase III clinical study of Insulin Glargine in Adults with Type 2 Diabetes.CTRI/2021/11/037994M J Biopharm Pvt Ltd
尚未招募
3 期
A study to evaluate the Safety and Effectiveness of Tofacitinib Gel versus Minoxidil Solution in Treatment of Adult Male Patients with Androgenetic Alopecia.CTRI/2022/09/045412MACLEODS PHARMACEUTICALS LTD
尚未招募
4 期
To Assess the Safety and Efficacy of Imusil tablet in Treatment of Adult Subjects with mild COVID-19CTRI/2022/02/040687Glowderma Lab Private Limited